Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Identity XT: Semagacestat Open-Label Extension in Alzheimer's Disease
NCT01035138Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2009
- Primary completion
- Apr 2011
- Modality
- Peptides, Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of semagacestat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Dec 2009; status: completed.
02
Drugs
semagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01035138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035138.